ORTEXORTEX News
Tracking VEON? Get live short interest, options flow, and signals on ORTEX.Sign up free →
VE
Trader NoteVEON

VEON Options Flash Bullish Extreme as Cost to Borrow Spikes

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 23 Sept 2026, 19:32

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

VEON enters the final week of September carrying a sharp tension: the options market has swung to its most aggressively bullish posture of the past year, even as borrowing costs have surged almost 100x from where they sat a month ago.

The options signal is the standout this week. The put/call ratio has collapsed to 0.16 — its lowest level in the past 52 weeks, which ran as high as 2.21 — and that reading sits more than two standard deviations below the 20-day average of 0.37. That kind of PCR compression points to unusually heavy call-side positioning: traders are buying upside, not hedging downside. The shift has been rapid; as recently as mid-August the PCR was running above 0.60, meaning the options skew has essentially flipped in five weeks. With the stock up nearly 17% over the past month and closing at $69.37, the momentum has clearly caught options traders' attention.

The borrow market tells a more complicated story. Cost to borrow has rocketed to 6.1%, roughly double where it was a week ago and a world away from the near-zero levels (0.07–0.87%) that prevailed through most of August. That move — nearly 3,600% over 30 days — is dramatic, though borrow availability remains overwhelmingly loose: over 4,400% of short interest is available in the lending pool, well above the 52-week floor of 890%, which means there is no squeeze dynamic at work. Short interest itself is negligible at 0.30% of the free float, barely changed on the week. The CTB spike reflects shifts in supply and demand at the margins of the borrow market, not a building short conviction. The days-to-cover figure from the latest FINRA settlement (2.57 days) confirms the short book is thin.

The ownership structure deserves attention on this name. LPE Middle East Limited — part of the Letterone complex controlled by Mikhail Fridman's investment group — filed a Schedule 13D/A as recently as December 2025, declaring a 45.5% stake. That activist filing is on record and carries the standard caveat that disclosed stakes are event-driven snapshots; positions can change without a further filing once they drift below 5%. Separately, Lingotto Investment Management (the Agnelli family's investment arm) filed a 13G/A in August 2026 showing its stake trimmed to 7.1% from a prior 8.7%. Shah Capital also trimmed slightly through June. On the insider side, Director Augie Fabela made open-market purchases totalling roughly $1.1 million across two days in early August at prices in the mid-$50s — not under a 10b5-1 plan, and therefore carrying more signal weight than a scheduled sale would. The stock has since risen roughly 25% from those purchase prices.

Earnings history is thin but directionally positive. The most recent confirmed print (May 13 Q1 release) produced a +7.8% single-day gain and a +10.2% five-day move. The subsequent July print showed a much smaller 1-day reaction, though the five-day drift was still positive at 8.2%. The next event is scheduled for November 6.

Valuation is undemanding for a stock that has moved this far this fast. The trailing P/E runs at roughly 8.7x, with EV/EBITDA at 3.4x — both of which have expanded modestly over 30 days but remain well below typical emerging-market telecom comparables. The ORTEX short score of 30.9 is low (below 50 signals limited short pressure), consistent with a float that is institutionally concentrated and lightly shorted. Closest listed peers TIGO and KYIV both slipped on the week, falling roughly 1.5% each, while VEON added nearly 1% — a modest but notable divergence given the shared frontier-market exposure.

The November 6 earnings date is the focal point to watch: with options fully skewed toward the call side and the stock carrying a 17% one-month gain into the release, how the print lands against the growth guidance communicated through the year — 12–15% EBITDA expansion — will determine whether the bullish positioning in the options market finds fundamental support.

Stocks in this article

See the live data behind this article on ORTEX.

Open VEON on ORTEX →

How this article was generated

Generated
23 Sept 2026, 19:41
Data as of
23 Sept 2026, 19:32
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.